Hiramatsu Kyoko, Takahashi Keiichi, Yamaguchi Taturo, Matsumoto Hiroshi, Miyamoto Hidenori, Tanaka Souichi, Tanaka Chikako, Tamamori Yoshiko, Imajo Mari, Kawaguchi Masashi, Toi Masakazu, Mori Takeo, Kawakita Masao
Medical Research and Development Center, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Clin Cancer Res. 2005 Apr 15;11(8):2986-90. doi: 10.1158/1078-0432.CCR-04-2275.
N(1),N(12)-diacetylspermine (DiAcSpm) in the urine of colorectal and breast cancer patients was examined to establish its usefulness as a novel diagnostic tool for detecting these cancers at clinically early stages.
Urine samples from 248 colon cancer patients and 83 breast cancer patients as well as 51 patients with benign gastrointestinal diseases treated in Tokyo Metropolitan Komagome Hospital during the period of August 1999 to January 2004 were collected. DiAcSpm was analyzed by ELISA and its sensitivity for malignant conditions was compared with that of serum carcinoembryonic antigen (CEA), CA19-9, and CA15-3.
The sensitivity of urinary DiAcSpm for colon cancer patients (n = 248) was 75.8% (mean +/- 2 SD for 52 healthy controls as a cutoff value), which was markedly higher than the sensitivities of serum CEA (39.5%, P < 0.0001) and CA19-9 (14.1%, P < 0.0001). DiAcSpm was elevated in 60% of tumor-node-metastasis cancer stage 0 + I patients, whereas only 10% (P < 0.0001) and 5% (P < 0.0001) of these patients were CEA- and CA19-9-positive, respectively. The sensitivity of urinary DiAcSpm for 83 cases of breast cancer (60.2%) was higher than the sensitivities of CEA (37.3%, P = 0.0032) and CA15-3 (37.3%, P = 0.0032). DiAcSpm was elevated in 28% of tumor-node-metastasis stage I + II patients, whereas only 3% (P = 0.0064) and 0% (P = 0.001) of these patients were CEA- and CA15-3-positive, respectively.
The observations indicate that urinary DiAcSpm is a more sensitive marker than CEA, CA19-9, and CA15-3 and that it can efficiently detect colorectal and breast cancers at early stages.
检测结直肠癌和乳腺癌患者尿液中的N(1),N(12)-二乙酰精胺（DiAcSpm），以确定其作为临床早期检测这些癌症的新型诊断工具的效用。
收集了1999年8月至2004年1月期间在东京都驹込医院接受治疗的248例结肠癌患者、83例乳腺癌患者以及51例良性胃肠道疾病患者的尿液样本。通过酶联免疫吸附测定法（ELISA）分析DiAcSpm，并将其对恶性疾病的敏感性与血清癌胚抗原（CEA）、CA19-9和CA15-3的敏感性进行比较。
尿液DiAcSpm对结肠癌患者（n = 248）的敏感性为75.8%（以52名健康对照的平均值±2标准差作为临界值），明显高于血清CEA（39.5%，P < 0.0001）和CA19-9（14.1%，P < 0.0001）的敏感性。在肿瘤-淋巴结-转移癌0 + I期患者中，60%的患者DiAcSpm升高，而这些患者中分别只有10%（P < 0.0001）和5%（P < 0.0001）的患者CEA和CA19-9呈阳性。尿液DiAcSpm对83例乳腺癌患者的敏感性（60.2%）高于CEA（37.3%，P = 0.0032）和CA15-3（37.3%，P = 0.0032）的敏感性。在肿瘤-淋巴结-转移I + II期患者中，28%的患者DiAcSpm升高，而这些患者中分别只有3%（P = 0.0064）和0%（P = 0.001）的患者CEA和CA15-3呈阳性。
这些观察结果表明，尿液DiAcSpm是一种比CEA、CA19-9和CA15-3更敏感的标志物，并且能够在早期有效地检测结直肠癌和乳腺癌。
